High-intensity chemotherapy and breast cancer

Published in the July No. 1 on the International Journal of Cancer study shows that use of autologous blood stem cell support for high-intensity chemotherapy, high-risk primary independent prognostic factor in patients with P53 and Her2/neu overexpression.

ManfredHensel the University of Heidelberg in Germany, Dr. pointed out that previous study found that P53 and Her2/neu conventional treatment prognostic factors. Moreover, the high risk associated with axillary lymph node metastasis in patients with conventional chemotherapy and poor prognosis. To this end, the researchers began to study since 1992, autologous blood stem cell transplantation-assisted high-intensity chemotherapy treatment.

The researchers selected the commonly used clinical parameters such as tumor size, axillary lymph node number and a few other commonly used laboratory parameters, including hormone receptor levels and tumor grade, to evaluate the prognosis. Also used immunohistochemistry to analyze tumor molecular markers, it is surprised to that of conventional clinical parameters of predictive value of less than the modern molecular marker.

Dr. Hensel pointed out that the multi-variable analysis showed that high-dose chemotherapy is the best prognostic factors, and Her2/neu overexpression of P53, and the relative risk were 6.06 and 3.86.

Dr. Hensel, high-intensity chemotherapy may be used in the future, P53, and Her2/neu overexpression in patients, while other patients may need to use other treatment options such as: antibody therapy, cancer vaccines and cell therapy.